Search Results (1 to 10 of 1836 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 510 Journal of Medical Internet Research
- 336 JMIR Research Protocols
- 206 JMIR Formative Research
- 146 JMIR mHealth and uHealth
- 87 JMIR Public Health and Surveillance
- 73 JMIR Mental Health
- 69 Online Journal of Public Health Informatics
- 58 JMIR Human Factors
- 46 JMIR Medical Informatics
- 32 JMIR Aging
- 29 JMIR Cancer
- 26 JMIR Dermatology
- 25 JMIR Medical Education
- 25 JMIR Serious Games
- 23 Interactive Journal of Medical Research
- 23 JMIR Pediatrics and Parenting
- 20 Iproceedings
- 16 JMIR Diabetes
- 15 JMIR Infodemiology
- 15 JMIR Rehabilitation and Assistive Technologies
- 14 JMIRx Med
- 8 JMIR AI
- 8 JMIR Perioperative Medicine
- 7 Journal of Participatory Medicine
- 5 JMIR Nursing
- 4 JMIR Cardio
- 3 JMIR Biomedical Engineering
- 2 JMIR Neurotechnology
- 1 Asian/Pacific Island Nursing Journal
- 1 JMIR Bioinformatics and Biotechnology
- 1 JMIR Data
- 1 JMIR XR and Spatial Computing (JMXR)
- 1 Medicine 2.0
- 0 iProceedings
- 0 JMIR Preprints
- 0 JMIR Challenges
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Capturing Community Perspectives in a Statewide Cancer Needs Assessment: Online Focus Group Study
JMIR Cancer 2025;11:e63717
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
User Experience of Older Adults With an Age-Friendly Transportation Planning E-Tool: Scoping Review
JMIR Hum Factors 2025;12:e63273
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Sodium oxybate, the pharmacological agent used in this study, acts as a GABA-B receptor agonist and a precursor of GABA [24]. It was administered in doses ranging between 0.01 and 0.1 g/kg, 3 times daily either orally or intravenously (equivalent to 2.4-24 g/d for an 80 kg patient). Among patients with schizophrenia and catatonia, approximately 30 participants, the study showed a reduction of catatonic symptoms ranging from 60% to 70%.
JMIR Res Protoc 2025;14:e68356
Download Citation: END BibTex RIS